한빛사
>
한빛사논문
한빛사논문
- 조회236
J. Hematol. Oncol., May 20 2024, 17 (1) | https://doi.org/10.1186/s13045-024-01556-3
[Correspondence] Generation of sarconoids from angiosarcoma patients as a systematic-based rational approach to treatment
Da Jung Jung1, Jae Hee Byeon1, Young Chul Kim3, Woo Shik Jeong3, Jong-Woo Choi3,4* and Gi Seok Jeong1,2,5*
1Biomedical Engineering Research Center, Asan Institute for Life Sciences, Seoul, South Korea
2Department of Covergence Medicine, College of Medicine, University of Ulsan, Seoul, South Korea
3Department of Plastic and Reconstructive Surgery, Asan Medical Center, Seoul, South Korea
4Department of Plastic and Reconstructive Surgery, College of Medicine, University of Ulsan, Seoul, South Korea
5Department of Biomedical Engineering, College of Medicine, University of Ulsan, Seoul, South Korea
*Correspondence: Jong-Woo Choi, Gi Seok Jeong
Abstract
Angiosarcoma is a rare subtype of malignant neoplasm originating from vascular or lymphatic endothelial cells; its low incidence has posed significant challenges for comprehensive investigations into its pathogenic mechanisms and the development of innovative treatment modalities through in vitro and in vivo models. Recent endeavors spearheaded by patient-partnered research initiatives have aimed to elucidate the intricacies of angiosarcomas by leveraging biological omics approaches, with the overarching objective of enhancing prognostic indicators and therapeutic options for this uncommon pathology. To bridge the gap between preclinical research and translational applications, we engineered angiosarcoma-derived organoids from surgically resected primary tumors, hereafter referred to as "sarconoids," as a proof-of-concept model. A novel protocol for the establishment of these sarconoids has been developed and validated. To ensure that the sarconoids faithfully recapitulate the heterogeneity and complexities of the patients' original tumors, including transcriptomic signatures, cell-type specificity, and morphological traits, exhaustive histological and transcriptomic analyses were conducted. Subsequently, we expanded the scope of our study to include an evaluation of a sarconoid-based drug screening platform; for this purpose, a drug library (AOD IX), supplied by the National Cancer Institute's Developmental Therapeutics Program, was screened using 96-well plates. Our findings suggest that sarconoids can be reliably generated from angiosarcoma patient-derived tissues and can serve as accurate models for evaluating therapeutic responses, thereby holding far-reaching implications for translational research and clinical applications aimed at advancing our understanding and treatment of angiosarcoma.
논문정보
- Correspondence
- 2024년 05월 (BRIC 등록일 2024-05-20)
- 국내 연구진
- 바이오·의료융합 > 다학제 융합/복합
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
